Depressive DisordersPsilocybin

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world

The authors developed and validated the Watts Connectedness Scale (WCS), a three‑dimensional measure of felt connectedness to self, others and the wider world that demonstrated a stable factor structure and good internal consistency. WCS scores rose significantly after psychedelic experiences—correlating with mystical, emotional‑breakthrough and communitas measures—and increased more after psilocybin therapy than escitalopram in a randomised controlled trial, indicating sensitivity to therapeutically relevant change.

Authors

  • Carhart-Harris, R. L.
  • Gandy, S.
  • Kaelen, M.

Published

Psychopharmacology
individual Study

Abstract

AbstractRationaleA general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of ‘connectedness’ as ‘a state of feeling connected to self, others and the wider world’. Existing tools for measuring connectedness have focused on particular aspects of connectedness, such as ‘social connectedness’ or ‘nature connectedness’, which we hypothesise to be different expressions of a common factor of connectedness. Here, we sought to develop a new scale to measure connectedness as a construct with these multiple domains. We hypothesised that (1) our scale would measure three separable subscale factors pertaining to a felt connection to ‘self’, ‘others’ and ‘world’ and (2) improvements in total and subscale WCS scores would correlate with improved mental health outcomes post psychedelic use.ObjectivesTo validate and test the ‘Watts Connectedness Scale’ (WCS).MethodsPsychometric validation of the WCS was carried out using data from three independent studies. Firstly, we pooled data from two prospective observational online survey studies. The WCS was completed before and after a planned psychedelic experience. The total sample of completers from the online surveys wasN = 1226. Exploratory and confirmatory factor analysis were performed, and construct and criterion validity were tested. A third dataset was derived from a double-blind randomised controlled trial (RCT) comparing psilocybin-assisted therapy (n = 27) with 6 weeks of daily escitalopram (n = 25) for major depressive disorder (MDD), where the WCS was completed at baseline and at a 6-week primary endpoint.ResultsAs hypothesised, factor analysis of all WCS items revealed three main factors with good internal consistency. WCS showed good construct validity. Significant post-psychedelic increases were observed for total connectedness scores (η2 = 0.339,p < 0.0001), as well as on each of its subscales (p < 0.0001). Acute measures of ‘mystical experience’, ‘emotional breakthrough’, and ‘communitas’ correlated positively with post-psychedelic changes in connectedness (r = 0.42,r = 0.38,r = 0.42, respectively,p < 0.0001). In the RCT, psilocybin therapy was associated with greater increases in WCS scores compared with the escitalopram arm (ηp2 = 0.133, p = 0.009).ConclusionsThe WCS is a new 3-dimensional index of felt connectedness that may sensitively measure therapeutically relevant psychological changes post-psychedelic use. We believe that the operational definition of connectedness captured by the WCS may have broad relevance in mental health research.

Unlocked with Blossom Pro

Research Summary of 'The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world'

Study Details

Cited By (24)

Papers in Blossom that reference this study

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

Carter, O., Castle, D., Iyer, R. et al. · Therapeutic Advances in Psychopharmacology (2025)

Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies

Carhart-Harris, R. L., Erritzoe, D., Giribaldi, B. et al. · Frontiers in Psychology (2025)

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression

Carhart-Harris, R. L., Demetriou, L., Erritzoe, D. et al. · American Journal of Psychiatry (2025)

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises

Carhart-Harris, R. L., Erritzoe, D., Harding, R. et al. · Molecular Psychiatry (2025)

2 cited
Processing of self-related thoughts in experienced users of classic psychedelics and non-users: a source localisation EEG study

Bola, M., Brzezicka, A., Hobot, J. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025)

1 cited
Clinically relevant acute subjective effects of psychedelics beyond mystical experience

Goldy, S. P., Griffiths, R. R., Weiss, B. et al. · Nature Reviews Psychology (2024)

Show all 24 papers
Psychedelics and the 'inner healer': Myth or mechanism?

Barba, T., Carhart-Harris, R. L., Erritzoe, D. et al. · Journal of Psychopharmacology (2024)

11 cited
Psychedelics and sexual functioning: a mixed-methods study

Barba, T., Carhart-Harris, R. L., Erritzoe, D. et al. · Scientific Reports (2024)

19 cited
Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model

Beller, N., Campbell, W. K., Erritzoe, D. et al. · Journal of Psychedelic Studies (2023)

10 cited
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research

Jacobs, E., Murphy-Beiner, A., Nutt, D. J. et al. · Neuroethics (2023)

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder

Bentancourt, I., Bramen, J., Heinzerling, K. G. et al. · Frontiers in Psychiatry (2023)

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change

Carhart-Harris, R. L., Monson, C. M., Wagner, A. C. et al. · Journal of Affective Disorders (2023)

47 cited
Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca

Campbell, W. K., Erritzoe, D., Weiss, B. et al. · Scientific Reports (2023)

Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia

Gandy, S., Harrild, F., Irvine, A. et al. · Psychoactives (2023)

17 cited
Changed Substance Use After Psychedelic Experiences Among Individuals in Canada

Boehnke, K. F., Kruger, D. J., Lucas, P. · International Journal of Mental Health and Addiction (2023)

11 cited
On the need for metaphysics in psychedelic therapy and research

Sjöstedt-Hughes, P. · Frontiers in Psychology (2023)

Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience

Cooke, J., Craste, E. G., Kałużna, A. et al. · Journal of Psychedelic Studies (2022)

Your Library